S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells

Oncology Letters

Volumn 9, Issue 6, 2015, Pages 2864-2870

  Capoccia, Elena ^a   Cirillo, Carla ^b   Marchetto, Annalisa ^a   Tiberi, Samanta ^a   Sawikr, Youssef ^a   Pesce, Marcella ^c   D'alessandro, Alessandra ^c   Scuderi, Caterina ^a   Sarnelli, Giovanni ^c   Cuomo, Rosario ^c   Steardo, Luca ^a   Esposito, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Glioma cells; p53; Pentamidine; S100 calcium binding protein B

Indexed keywords

AQUAPORIN 4; BETA ACTIN; CALCIUM BINDING PROTEIN; GENOMIC DNA; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; PENTAMIDINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PROTEIN S100B;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION ASSAY; CELL SURVIVAL; CELL VIABILITY; CHROMATIN; CONTROLLED STUDY; DNA FRAGMENTATION ASSAY; DOWN REGULATION; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; GLIOMA; GLIOMA CELL LINE; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; MIGRATION INHIBITION; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; UPREGULATION; WESTERN BLOTTING; WOUND HEALING;

EID: 84929996128     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3091     Document Type: Article

References (38)

1. Mamelak AN and Jacoby DB: Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv 4: 175-186, 2007.
2. Goodenberger ML and Jenkins RB: Genetics of adult glioma. Cancer Genet 205: 613-621, 2012.
3. Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, et al; RARECARE Working Group: Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer 48: 1532-1542, 2012.
4. Stupp R, Pavlidis N and Jelic S; ESMO Guidelines Task Force: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol 16 (Suppl 1): i64-i65, 2005.
5. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 2001.
6. Giese A, Rief MD, Loo MA and Berens ME: Determinants of human astrocytoma migration. Cancer Res 54: 3897-3904, 1994.
7. Louis DN, Pomeroy SL and Cairncross JG: Focus on central nervous system neoplasia. Cancer Cell 1: 125-128, 2002.
8. Donato R, Sorci G, Riuzzi F, et al: S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 1793: 1008-1022, 2009.
9. Chaves ML, Camozzato AL, Ferreira ED, et al: Serum levels of S100B and NSE proteins in Alzheimer's disease patients. J Neuroinflammation 7: 6, 2010.
10. Sathe K, Maetzler W, Lang JD, et al: S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. Brain 135: 3336-3347, 2012.
11. Weide B, Richter S, Büttner P, et al: Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PLoS One 8: e81624, 2013.
12. Lin J, Yang Q, Yan Z, Markowitz J, Wilder PT, Carrier F and Weber DJ: Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem 279: 34071-34077, 2004.
13. Rustandi RR, Baldisseri DM and Weber DJ: Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nat Struct Biol 7: 570-574, 2000.
14. Millward TA, Heizmann CW, Schäfer BW and Hemmings BA: Calcium regulation of Ndr protein kinase mediated by S100 calcium-binding proteins. EMBO J 17: 5913-5922, 1998.
15. Arcuri C, Bianchi R, Brozzi F and Donato R: S100B increases proliferation in PC12 neuronal cells and reduces their responsiveness to nerve growth factor via Akt activation. J Biol Chem 280: 4402-4414, 2005.
16. Hartman KG, McKnight LE, Liriano MA and Weber DJ: The evolution of S100B inhibitors for the treatment of malignant melanoma. Future Med Chem 5: 97-109, 2013.
17. Smith J, Stewart BJ, Glaysher S, Peregrin K, Knight LA, Weber DJ and Cree IA: The effect of pentamidine on melanoma ex vivo. Anticancer Drugs 21: 181-185, 2010.
18. Sibenaller ZA, Etame AB, Ali MM, Barua M, Braun TA, Casavant TL and Ryken TC: Genetic characterization of commonly used glioma cell lines in the rat animal model system. Neurosurg Focus 19: E1, 2005.
19. Amberger VR, Hensel T, Ogata N and Schwab ME: Spreading and migration of human glioma and rat C6 cells on central nervous system myelin in vitro is correlated with tumor malignancy and involves a metalloproteolytic activity. Cancer Res 58: 149-158, 1998.
20. Gunnersen JM, Spirkoska V, Smith PE, Danks RA and Tan SS: Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression. Glia 32: 146-154, 2000.
21. Grobben B, DE Deyn PP and Slegers H: Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res 310: 257-270, 2002.
22. Schlegel J, Piontek G, Kersting M, Schuermann M, Kappler R, Scherthan H, et al: The p16/Cdkn2a/Ink4a gene is frequently deleted in nitrosourea-induced rat glial tumors. Pathobiology 67: 202-206, 1999.
23. Asai A, Miyagi Y, Hashimoto H, Lee SH, Mishima K, Sugiyama A, et al: Modulation of tumor immunogenicity of rat glioma cells by s-Myc expression: eradication of rat gliomas in vivo. Cell Growth Differ 11: 1153-1158, 1994.
24. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
25. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
26. Renault-Mihara F, Beuvon F, Iturrioz X, Canton B, De Bouard S, Léonard N, et al: Phosphoprotein enriched in astrocytes-15 kDa expression inhibits astrocyte migration by a protein kinase C delta-dependent mechanism. Mol Biol Cell 17: 5141-5152, 2006.
27. Clarke J, Butowski N and Chang S: Recent advances in therapy for glioblastoma. Arch Neurol 67: 279-283, 2010.
28. Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J and Meyermann R: BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci 155: 68-75, 1998.
29. Paul-Samojedny M, Kokocińska D, Samojedny A, Mazurek U, Partyka R, Lorenz Z and Wilczok T: Expression of cell survival/death genes: Bcl-2 and Bax at the rate of colon cancer prognosis. Biochim Biophys Acta 1741: 25-29, 2005.
30. Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C and Yi T: Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther 1: 1255-1264, 2002.
31. Zimmer DB, Lapidus RG and Weber DJ: In vivo screening of S100B inhibitors for melanoma therapy. Methods Mol Biol 963: 303-317, 2013.
32. Du R, Petritsch C, Lu K, Liu P, Haller A, Ganss R, et al: Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol 10: 254-264, 2008.
33. Ding T, Zhou Y, Sun K, Jiang W, Li W, Liu X, et al: Knockdown a water channel protein, aquaporin-4, induced glioblastoma cell apoptosis. PLoS One 8: e66751, 2013.
34. Verkman AS: Aquaporins in clinical medicine. Annu Rev Med 63: 303-316, 2012.
35. Giese A: Glioma invasion-pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumorsuppressor p53 and proto-oncogene ETS-1. Acta Neurochir Suppl 88: 153-162, 2003.
36. Sanderson L, Dogruel M, Rodgers J, et al: Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. J Pharmacol Exp Ther 329: 967-977, 2009.
37. Kotthaus J, Kotthaus J, Schade D, et al: New prodrugs of the antiprotozoal drug pentamidine. ChemMedChem 9: 2233-2242, 2011.
38. Raseroka BH and Ormerod WE: The trypanocidal effect of drugs in different parts of the brain. Trans R Soc Trop Med Hyg 80: 634-641, 1986.